Pharma Business Week articles from September 2003

Pharma Business Week archives from September 2003

Data show Enterra therapy reduces persistent nausea, vomiting.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- According to newly reported research in Gastroenterology, high-frequency, low-energy gastric electrical stimulation (GES) of the stomach with Enterra Therapy from Medtronic, Inc., (MDT) reduces many of...

Phase I clinical testing of ACP-103 complete.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Acadia Pharmaceuticals has successfully completed phase I clinical testing of ACP-103, the company's proprietary small molecule 5-HT2A inverse agonist. The study was designed to evaluate the...

First component of rolling NDA submitted for RSR13.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Allos Therapeutics, Inc., (ALTH) announced that it has begun submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the company's investigational radiation...

Trial tests treatment for postmenopausal cancer patients who relapse.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- AstraZeneca announced that patient recruitment has begun on an important new trial involving its novel estrogen receptor antagonist, "Faslodex" (fulvestrant). The trial, called EFECT, is designed...

Human Genome Sciences announces license agreement.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Human Genome Sciences, Inc., (HGSI) announced a license agreement with Genentech, Inc., (DNA). Under this agreement, Genentech has acquired exclusive, worldwide patent rights to develop and...

Early-stage pharmaceuticals: R&D spending doubles, NDAs plummet.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- New drug approvals have plummeted from 53 new molecular entities approved in 1996 to just 26 in 2002; at the same time, R&D spending has nearly doubled from $17 billion in 1996 to $32 billion last year,...

Patient enrollment completed in phase IIb CART-2 study with AGI-1067.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- AtheroGenics, Inc., (AGIX) has recently completed enrollment in a phase IIb clinical trial evaluating its proprietary v-protectant drug candidate, AGI-1067, as a treatment for atherosclerosis and...

FDA approves Photofrin for the ablation of high-grade dysplasia.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Axcan Pharma, Inc., announced that it has received approval from the U.S Food and Drug Administration (FDA) for the use of Photofrin photodynamic therapy (PDT) in the ablation of high-grade dysplasia...

$50,000 development grant will support Oregon's bioscience industry.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- The Oregon Bioscience Association (OBA) announced a partnership between the association and the Oregon Economic and Community Development Department (OECDD), a state organization whose mission is to...

Liposome technology company initiates cooperative alliance.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- CytoGenix, Inc., (CYGX) has completed an agreement with BioZone Laboratories, Inc., of Pittsburg, California, to investigate the synergy of their technologies to develop and test new formulations for...

Chemistry-driven drug discovery company realigns business mission.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- In a further step to continually adapt its organization and technology platform to best meet the needs of the pharmaceutical industry, ChemCodes is accelerating its plans for internal compound...

Agreement signed for use of chemical assay.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Avitar, Inc., (AVR) announced that it has signed a Letter of Understanding with Immunomatrix, Inc., for the exclusive right to utilize Immunomatrix's high sensitivity chemical assay technologies in...

Pharmaceutical firm to help state AIDS programs.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Company (BMY) announced an agreement with the state-administered AIDS Drug Assistance Programs (ADAPs) to provide interim emergency relief to help address the funding crisis facing...

Inpharmatica secures ADME service agreement with European pharmaceutical company.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Inpharmatica, Ltd., an informatics-driven drug discovery company, announced that it has entered into a nonexclusive ADME service agreement with Ionix Pharmaceuticals, Ltd., a European analgesic drug...

ADHD drug maker reports earnings of $0.31 per share.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Cephalon, Inc., (CEPH) reported results for the second quarter of 2003, which included total revenue of $168.8 million, product sales of $160.3 million, and diluted earnings per share of $0.31. ...

APF112 phase II submitted for FDA review; royalty income increases 11%.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- A.P. Pharma, Inc., (APPA) reported financial results for the 3 months ended June 30, 2003, reflecting increased royalty income and contract revenues as well as higher research and development expenses...

Allergan collaboration leads to increased revenues for pharmaceutical company.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Inspire Pharmaceuticals, Inc., (ISPH) reported financial results for the second quarter ended June 30, 2003. For the quarter ended June 30, 2003, the company reported a net loss of $6.6 million, or...

Biotech company reports $0.36 per share loss.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Adolor Corporation (ADLR) reported financial results for the 3- and 6-month periods ended June 30, 2003. For the 3 months ended June 30, 2003, the company reported a net loss of $11.5 million or...

Biotherapeutics company reports loss of $0.24 per share.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Applied Molecular Evolution, Inc., (AME, AMEV) reported financial results for the second quarter of 2003. For the quarter ended June 30, 2003, the company reported a net loss of $5.0 million or...

Drug delivery company reports $0.47 per share loss.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Alkermes, Inc., (ALKS) reported its financial results for the 3-month period ended June 30, 2003. The net loss on a GAAP basis for the quarter ended June 30, 2003, was $30.6 million or $0.47 per...

Drug discovery company meets second quarter expectation, initiates trials.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Exelixis, Inc., (EXEL) reported financial results for the quarter ended June 30, 2003. For the quarter ended June 30, 2003, the company reported a net loss of approximately $23.4 million, or $0.39...

Drug discovery firm meets analysts' estimate for revenues, earnings.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) reported financial results for the fourth quarter and full year of fiscal 2003, ended June 30, 2003. During the fourth quarter of fiscal 2003, Array reported total...

Hormone therapy company raises $10.3M in private placement.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BISP) announced that it has raised $10.3 million through the private placement of approximately 4.8 million newly issued shares of BioSante common stock to several new...

Immunology company reports financial results, discusses Aventis collaboration.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- ImmunoGen, Inc., (IMGN) announced financial results for the 3- and 12-month periods ended June 30, 2003. For the 3-month period, the company reported a net loss of $6.9 million, or $0.17 per basic...

Oncology drug maker reports 66% increase in revenue.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Aeterna Laboratories, Inc., (AEL; AELA) reported total revenues for the second quarter ended June 30, 2003, of $38.9 million, an increase of 66% compared with total revenues of $23.4 million for the...

Pharmaceutical company reports net loss of $0.01 per share.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- AutoImmune, Inc., (AIMM) reported a net loss of $0.14 million, or $0.01 per share basic and diluted, for the 3 months ended June 30, 2003, compared with a net loss of $0.18 million, or $0.01 per share...

Pharmaceutical distributor reports earnings of $0.29 per share.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- D&K Healthcare Resources, Inc., (DKHR) reported diluted earnings per share (EPS) of $0.29 on net income of $4.2 million for the fourth quarter fiscal 2003 ended June 30, 2003. The results compare...

Pharmaceutical firm reports earnings of $2.43 per share.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Barr Laboratories, Inc., (BRL) reported revenues of $902.9 million and net earnings of $167.6 million, or $2.43 per fully diluted share for its fiscal year ended June 30, 2003, which included charges of...

Pharmaceutical firm reports loss of $0.14 per share.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- BioMarin Pharmaceutical, Inc., (BMRN) announced financial results for its second quarter ended June 30, 2003. The net loss was $9.1 million ($0.14 per share) for the second quarter of 2003 compared...

Pulsatile drug company files with SEC for IPO.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Advancis Pharmaceutical Corporation announced that it filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) of its common stock....

Ribapharm parent reports second quarter 2003 net income of $14.9 million.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- ICN Pharmaceuticals, Inc., (ICN) announced second quarter 2003 revenues of $183.5 million, compared with $180.8 million in the same period last year. ICN also reported net income for the 2003 second...

Rosacea drug maker increases guidance for 2003.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Bradley Pharmaceuticals, Inc., (BDY) released guidance for estimated net sales and earnings per share for the year 2003. These projections represent an increase over the previous guidance set on...

Venture capital group invests in chloroplast DNA company.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Harris & Harris Group, Inc., announced it has invested $525,900 as part of a convertible preferred financing of privately held Chlorogen, Inc. Investors in this financing include Burrill & Co.,...

Women's health drug maker reports loss of $0.12 per share.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Columbia Laboratories (COB) announced financial results for the second quarter and 6 months ended June 30, 2003. For the second quarter of 2003, the company reported a loss of $4,366,608, or $0.12...

Series B financing raises $26.4M to fund infectious disease program.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- ActivBiotics, Inc., announced an initial closing of $26.4 million on its Series B round of financing. MDS Capital Corp. led the funding round that included other new investors BioVentures...

BlockAide trial to begin in fourth quarter; scientific advisory board formed.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Adventrx Pharmaceuticals, Inc., (AVRX) announced the formation of its new scientific advisory board, consisting of three well-known academic experts in the areas of anticancer and antiviral development....

Patent granted for ISA247, a calcineurin inhibitor.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Isotechnika, Inc., has received an issue notification from the United States Patent and Trademark Office regarding its immunosuppressive compound ISA247. This application has been issued United...

Gilead inks nonexclusive HCV licensing agreement, initiate research programs.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Gilead Sciences, Inc., (GILD) announced that it has entered into a nonexclusive licensing agreement with Chiron Corp. for the research, development, and commercialization of small molecule therapeutics...

Coronary heart disease market to reach $23B in 2012.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the total market value of drugs to treat coronary heart disease (CHD) could reach...

FTC clears Biogen merger.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- IDEC Pharmaceuticals Corp. (IDPH) and Biogen, Inc., (BGEN) announced that the Federal Trade Commission has completed its review of their proposed merger and granted early termination of the waiting...

Genesis Bioventures announces merger.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Genesis Bioventures, Inc., (GBI) announced the signing of a formal letter of intent to merge with Corgenix Medical Corp. (CONX) of Denver, Colorado. Under the terms of the letter of intent, Genesis...

Pharmaceutical research company buys Clinical Pharmacology Associates.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- SFBC International, Inc., (SFCC) has completed the acquisition of Clinical Pharmacology Associates (CP), based in Miami, Florida. The agreement provides for the acquisition of CP for approximately...

Big pharma orders make for successful commercial launch for Dynaflow.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- The Swedish biotech tools company Cellectricon has received orders from three of the top five pharmaceutical companies. The orders verify that major pharmaceutical companies will adopt the Dynaflow...

First Flexogan order delivered to Canadian retailer.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- AlphaRx, Inc., (ALRX) announced their first product delivery. Flexogan, AlphaRx's topical pain reliever, has been delivered to Loblaw Companies Limited, a mass market retailer in Canada. Flexogan,...

Anderson joins scientific advisory board at cancer drug firm.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Callisto Pharmaceuticals, Inc., (CLSP) announced that Kenneth C. Anderson, director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute and professor of medicine at Harvard...

Dr. Bernd Wetzel joins biotech company's supervisory board.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Direvo Biotech, AG, announced the appointment of Professor Dr. Bernd Wetzel, the former head of worldwide research and nonclinical development at Boehringer Ingelheim, to the company's supervisory...

Durrant named president of pediatric drug firm.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- The board of directors of PediaMed Pharmaceuticals, Inc., announced the appointment of Cameron Durrant, MD, as president. He will be reporting to and sitting on the board of PediaMed. A...

Martone appointed head of medical affairs at pharmaceutical firm.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Cubist Pharmaceuticals, Inc., (CBST) announced the appointment of William J. Martone, MD, as executive director, medical affairs. The company also announced that it has hired the first of three...

Physicians using online marketing content, spending less time with sales reps.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- As the number of pharmaceutical sales representatives has almost doubled in the last 5 years, so has the competition to spend time with the most valuable physicians, those writing a high volume of...

FDA gives green light to U.S. phase I clinical trials for Psoraxine.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Astralis, Ltd., (ASTR) announced that the U.S. Food and Drug Administration (FDA) has allowed the company to start phase I clinical trials in the U.S. for Psoraxine for the treatment of moderate to...

Happy Valley Medical strikes deal to evaluate Ceracor.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Happy Valley Medical, Inc., announced that it has entered into a research alliance with Edwards Lifesciences Corp. (EW) to evaluate the antiproliferative and antirestenotic properties of C6-ceramide in...

Biotech firm reports conditional continued listing on NASDAQ SmallCap.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- BioSpecifics Technologies Corp. (BSTCE) has been notified by The NASDAQ Stock Market that the NASDAQ Listing Qualifications Panel has determined to continue the listing of the company's common stock on...

Infectious disease-focused company approved for AMEX.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Immtech International, Inc., (IMM) announced its common stock has been approved for listing on the American Stock Exchange (AMEX). Immtech is expected to have Bear Wagner Specialists, LLC, as the...

Devices and prescription drugs driving growth in U.S. pain management market.
September 1, 2003... 2003 SEP 1 - (NewsRx.com & NewsRx.net) -- Medtech Insight, LLC, in its newly published "Pharmacological and Device-Based Therapeutic Approaches to Pain Management," addresses how devices and prescription medications are driving the U.S. pain...

Proper diagnosis of Parkinson disease to drive growth of therapies market.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Clinical misdiagnosis or under-diagnosis of Parkinson disease (PD) is curbing the market potential for its therapies in the U.S. Pharmaceutical majors are stepping up their efforts to enhance...

Patient-controlled regional anesthesia offers advantages for home use.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- The University of Florida College of Medicine performed a randomized, double-blind, placebo-controlled clinical study to determine the effectiveness of continuous interscalene brachial plexus block for...

Oncology drug makers sign agreement for AGRO100.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Aptamera announced that it has signed a product development and license agreement with Archemix Corp. for Aptamera's investigational anticancer drug, AGRO100. As part of this agreement, Archemix,...

Positive follow-up results reported from trial of Telcyta.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Telik, Inc., (TELK) reported positive follow-up data from a phase II clinical trial of Telcyta (TLK286) in patients with non-small cell lung cancer whose disease progressed following platinum-containing...

Sexual dysfunction and andropause lead strong growth in men's segment.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- The $17 billion world market in pharmaceuticals for men's health is poised to grow rapidly in the next 5 years, according to a new market research study by Kalorama Information. The two therapeutic...

Collaboration targets development of RC-529 adjuvant.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Corixa Corp. (CRXA) and Apovia AG announced a research, development, and commercialization agreement for Corixa's synthetic adjuvant, RC-529. The multiyear agreement grants Apovia commercial rights...

Study links preschool snoring, asthma, and nighttime cough.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Preschool-age children who regularly snore have a higher prevalence of asthma and nighttime cough than children who do not snore, said a study published Chest, the peer-reviewed journal of the American...

Phase I study of recombinant Alpha 1-antitrypsin completed.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- ProMetic Life Sciences (PLI) and Arriva Pharmaceuticals, Inc., announced that their joint venture, Arriva-ProMetic Inc., has successfully completed a phase I clinical trial for its proprietary...

Pilot manufacturing facility for bacterial vaccines planned in Massachusetts.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Avant Immunotherapeutics, Inc., (AVAN) announced that it has reached agreement with MassDevelopment for Avant to occupy and build out a process development and pilot-manufacturing facility in...

TurboWorx' PowerCloud to help accelerate drug discovery.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- TurboWorx, Inc., announced that Organon International is successfully utilizing its PowerCloud software platform to efficiently utilize and dynamically allocate computing resources. Leveraging...

Genome Therapeutics receives payment for research milestone.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Genome Therapeutics Corp. (GENE) has received a payment from Amgen, Inc., for the completion of a milestone under their agreement aimed at utilizing genetic information to discover and commercialize new...

FDA clears Guglielmi Detachable Coils for expanded treatment.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Boston Scientific Corporation (BSX) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Guglielmi Detachable Coils (GDC) to treat all brain...

Cushion brings comfort to women during mammography.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- The Doris Kupferle Breast Center at Harris Methodist Fort Worth Hospital (HMFW) is now using a product called MammoPad, a foam cushion designed to relieve the discomfort some women experience during a...

FDA approval granted for a phase II clinical trial of GTI-2040.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Lorus Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved the U.S. National Cancer Institute's (NCI) Investigational New Drug Application (IND) to begin a phase...

NCI grants to be used to target KCNK9/TASK3 and WIP1/PP1MD genes.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Tularik, Inc., (TLRK) announced the company has received two phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) for approximately $500,000 to support the...

NDA to be submitted for hyperparathyroidism treatment.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NPSP) provided an overview of its late-stage development programs and announced its operating results for the 3 and 6 months ended June 30, 2003. The company's most...

Provider of cervical cancer screening in U.K to adopt SurePath.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- TriPath Imaging, Inc., (TPTH) announced that The Doctors Laboratory, a provider of private cervical cancer screening in the United Kingdom, has stated that they are adopting the SurePath solution for...

$2.2M clinical research contract announced.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Covalent Group, Inc., (CVGR) announced the awarding of a $2.2 million phase IV clinical research contract with a global pharmaceutical company. The study, which represents repeat business for...

Agreement targets identification, validation products for drug discovery.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Pierce Biotechnology, Inc., a division of Perbio Science AB (PBIO), and Amphioxus Cell Technologies announced a comarketing agreement involving two complementary platform technologies used in...

Disease biomarker research relationship signed with AstraZeneca.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Caprion Pharmaceuticals announced a research collaboration with AstraZeneca (AZN) to identify biomarkers for pain using Caprion's CellCarta proteomics discovery platform. Under the terms of the...

Distribution agreement expanded for PreciseSIM simulator systems.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Nucletron BV has announced that it has renewed its worldwide distribution agreement with Elekta for providing simulator systems. These simulators are sold by Elekta under the trade name PreciseSIM...

Drug delivery company expands advisory, consulting agreement.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- LAM Pharmaceutical, Corp. (LAMP; LAM; LAM) announced that it has executed a business advisory and consulting agreement extension with Stanton, Walker & Company, a New York-based advisory firm. ...

Genomics company launches comarketing partnership.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Affymetrix, Inc., (AFFX) and Ingenuity Systems announced the creation of a partnership to deliver the Ingenuity Pathways Analysis product to Affymetrix customers. The companies also announced that...

Vaccine maker selects WebForce Express to enhance sales force.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Dendrite International, Inc., (DRTE) announced that Nabi Biopharmaceuticals (NABI), has selected Dendrite's WebForce Express field sales channel management suite to enhance its sales force activities on...

Natural phytosterols, phytostanols reduce cholesterol.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Not all natural cholesterol fighters are equal. A study published in the August 13, 2003, edition of the Journal of the American Medical Association (JAMA) entitled "Herbal Extract Not Effective in...

Orphan designation filed for SARS antisense drug.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Avi BioPharma, Inc., (AVII, AVIIW, AVIIZ) announced that, based on positive preclinical data, it has filed an application with the U.S. Food and Drug Administration (FDA) to obtain orphan designation...

ICN announces expanded Kinerase licensing agreement.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- ICN Pharmaceuticals, Inc., (ICN) announced the signing of a license agreement that amends its current manufacturing license with Senetek, PLC, to expand ICN's Kinerase product line. The new license...

New emulsion technology provides for effective delivery of macrolide drugs.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- San Francisco-based Patent Discovery Corp. (PDC) has acquired exclusive rights to advanced drug delivery emulsion (ADDE), a new drug delivery technology that should allow the intravenous (IV)...

SBIR grant will help develop LEAP as screening platform.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- Cyntellect, Inc., a wholly owned subsidiary of Oncosis, LLC, announced that Oncosis has been awarded a small business innovation research (SBIR) phase II grant. The project, titled "A Novel...

Mass spectrometry system launched for functional assay development.
September 8, 2003... 2003 SEP 8 - (NewsRx.com & NewsRx.net) -- BioTrove, Inc., introduced the Momentum technology, a patented ultra high-throughput mass spectrometry service enabling microliter-scale functional assay development and screening of intractable targets...